1. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Issue 12 (December 2015) Authors: Farago, Anna F.; Le, Long P.; Zheng, Zongli; Muzikansky, Alona; Drilon, Alexander; Patel, Manish; Bauer, Todd M.; Liu, Stephen V.; Ou, Sai-Hong I.; Jackman, David; Costa, Daniel B.; Multani, Pratik S.; Li, Gary G.; Hornby, Zachary; Chow-Maneval, Edna; Luo, David; Lim, Jonathan E.; Iafrate, Anthon... Journal: Journal of thoracic oncology Issue: Volume 10:Issue 12(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Issue 2 (28th March 2016) Authors: Iyer, Radhika; Wehrmann, Lea; Golden, Rebecca L.; Naraparaju, Koumudi; Croucher, Jamie L.; MacFarland, Suzanne P.; Guan, Peng; Kolla, Venkatadri; Wei, Ge; Cam, Nicholas; Li, Gang; Hornby, Zachary; Brodeur, Garrett M. Journal: Cancer letters Issue: Volume 372:Issue 2(2016) Page Start: 179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗